News | April 28, 2010

Study Evaluates Calcified Coronary Lesion Atherectomy

The Diamondback 360 atherectomy catheter approaching a lesion, and following treatment.

April 28. 2010 – A trial examining the use of an orbital atherectomy device on calcified coronary lesions was granted U.S. Food and Drug Administration (FDA) unconditional approval this week.

The ORBIT II pivotal trial will evaluate the safety and effectiveness of the Cardiovascular Systems Inc. (CSI) Diamondback 360 atherectomy system in coronary vessels. CSI received conditional IDE approval for the ORBIT II study in January. The pivotal trial will initially enroll up to 100 patients at as many as 50 U.S. sites, with the potential to enroll up to 429 patients. Jeffrey Chambers, M.D., an interventional cardiologist with Metropolitan Cardiovascular Consultants, Minneapolis, is the principal investigator.

The Diamondback 360° is designed for removing calcific and fibrocalcific plaque. It uses a diamond-coated crown with an orbital mechanism of action to sand and remove hardened plaque, which may facilitate more effective stent placement and restoration of blood flow in the coronary arteries. The orbital action also allows continuous saline and blood flow through the lesion, which may be advantageous during treatment.

In 2008, CSI completed the ORBIT I coronary trial, the first in-human feasibility study, which enrolled 50 patients in India. The Diamondback 360 was shown to be successful in 98 percent of patients with calcified lesions, and the acute procedural success rate, including stent placement, was 94 percent. These results met the company’s safety and efficacy endpoints and were among the data the FDA considered in granting the ORBIT II investigational device exemption (IDE) approval.

“Coronary arterial disease is the most common form of heart disease in the United States, affecting more than 16 million people,” Chambers said. “After the successes of the ORBIT I study, we are eager to expand the number of coronary patients treated with the Diamondback 360°, and acquire acute and long-term data. We believe the unique features of the Diamondback 360° are designed specifically to remove calcified plaque in coronary arteries to facilitate stent placement.”

In August 2007, the FDA granted 510(k) clearance for the use of the Diamondback 360 as a therapy for PAD (peripheral arterial disease), and CSI commenced a U.S. product launch in September 2007.

For more information:

Related Content

The Rex Medical Revolution rotational atherectomy system incorporates continuous aspiration and has a dual indication for atherectomy and thrombectomy.  #VICA19 #VIVA2019

The Rex Medical Revolution rotational atherectomy system incorporates continuous aspiration and has a dual indication for atherectomy and thrombectomy. 

News | Atherectomy Devices | November 11, 2019
November 7, 2019 — The REVEAL FDA investigational device exemption (IDE) trial confirmed a favorable safety and effec
The AngioDynamics/Eximo Medical B-Laser represents a new atherectomy device. #VIVA2019 #VIVA #VIVA19

The AngioDynamics/Eximo Medical B-Laser atherectomy system.

News | Atherectomy Devices | November 07, 2019
November 7, 2019 — There was no difference between drug-coated balloons (DCB) vs.
Rex Medical Receives 510(k) Clearance for Revolution Peripheral Atherectomy System
Technology | Atherectomy Devices | September 13, 2019
Rex Medical L.P. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Revolution...
First U.S. Patients Treated With Second-Generation Pantheris Atherectomy Device
News | Atherectomy Devices | July 18, 2018
Avinger Inc. announced in June that several physicians have successfully treated over 40 patients for peripheral artery...
Avinger Receives FDA Clearance of Next-Generation Pantheris Device
Technology | Atherectomy Devices | May 24, 2018
Avinger Inc. announced that the company received 510(k) clearance from the U.S. Food & Drug Administration (FDA)...
Medtronic Receives FDA Clearance for Riptide Aspiration System
Technology | Atherectomy Devices | January 16, 2018
Medtronic plc announced the company’s Neurovascular business unit received U.S. Food and Drug Administration (FDA)...
Avinger Announces Treatment of First Patients With Next-Generation Pantheris
News | Atherectomy Devices | January 09, 2018
January 9, 2018 – Avinger Inc. announced that Arne Schwindt, M.D., a vascular surgeon at St.
Avinger Receives 510(k) Clearance for Pantheris Image-Guided Atherectomy Device Modifications
Technology | Atherectomy Devices | November 20, 2017
November 20, 2017 — Avinger Inc. announced in October that the company received 510(k) clearance from the U.S.
Avinger Receives CE Mark for In-Stent Restenosis Indication With Pantheris Image-Guided Atherectomy
Technology | Atherectomy Devices | September 29, 2017
Avinger Inc. recently announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the...
Ra Medical Systems Receives FDA Clearance for New Peripheral Artery Disease Treatment
Technology | Atherectomy Devices | May 30, 2017
The U.S. Food and Drug Administration (FDA) announced that it has granted market clearance to Ra Medical Systems for...
Overlay Init